Notching another deal in its efforts to extend the global reach of toripalimab, Junshi Biosciences Co. Ltd. granted Dr. Reddy’s Laboratories Ltd. rights to develop and commercialize the PD-1 inhibitor in a regional licensing agreement that could be worth as much as $728.3 million.
Generate Biomedicines Inc. and The University of Texas MD Anderson Cancer Center have established a strategic collaboration to jointly discover and codevelop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.
Quest Diagnostics Inc. evidently found what it was looking for, as it agreed to acquire Haystack Oncology Inc. in an all-cash deal valued at up to $450 million with $300 million at closing and $150 million contingent on meeting specific milestones. Haystack focuses on minimal residual disease (MRD) testing, which can detect residual or recurring cancer in its early stages and help guide therapy decisions using blood samples rather than biopsied tissue. The companies expect the transaction to close before the end of June.
Shanghai Junshi Biosciences Co. Ltd.’s anti-PD-1 monoclonal antibody toripalimab showed positive interim event-free survival (EFS) results in a phase III study to treat patients with resectable non-small-cell lung cancer (NSCLC). This is the world’s first phase III trial that shows perioperative treatment with an anti-PD-1 monoclonal antibody significantly extends EFS of patients with resectable NSCLC, according to Shanghai-based Junshi Biosciences.
Shanghai Junshi Biosciences Co. Ltd.’s anti-PD-1 monoclonal antibody toripalimab showed positive interim event-free survival (EFS) results in a phase III study to treat patients with resectable non-small-cell lung cancer (NSCLC). This is the world’s first phase III trial that shows perioperative treatment with an anti-PD-1 monoclonal antibody significantly extends EFS of patients with resectable NSCLC, according to Shanghai-based Junshi Biosciences.
Bridge Biotherapeutics Inc. has received FDA clearance to proceed with a first-in-human study of BBT-207, a potential broad-spectrum fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of non-small-cell lung cancer (NSCLC).
Researchers from The Chinese University of Hong Kong and collaborators have discovered a promising target for immunotherapy in non-small-cell lung carcinoma (NSCLC). Their study investigated the regulation of tumor-associated neutrophils (TANs), in particular TGF-β1/Smad3 signaling, and their response to the microenvironment in NSCLC patients.
Differences in the immune reactions between smokers and nonsmokers may explain why only 20% of patients with lung cancer respond to immunotherapy treatment. Understanding these differences in the evolution of lung cancer between smokers and nonsmokers could be the key to unlocking new treatments.
Alterations in hepatocyte growth factor receptor (c-Met) can be oncogenic in non-small-cell lung cancer (NSCLC) as well as other cancer types. Antibody-drug conjugates (ADCs) that target c-Met have been developed to treat c-Met-expressing tumors.
Researchers from Therapex Co. Ltd. recently reported the discovery and preclinical evaluation of a novel fourth-generation epidermal growth factor receptor (EGFR) inhibitor for overcoming C797S mutation-mediated acquired resistance in non-small-cell lung cancer (NSCLC), which has been reported as the most common acquired resistance mechanism in NSCLC.
